424 related articles for article (PubMed ID: 25712293)
1. HER2 expression status in diverse cancers: review of results from 37,992 patients.
Yan M; Schwaederle M; Arguello D; Millis SZ; Gatalica Z; Kurzrock R
Cancer Metastasis Rev; 2015 Mar; 34(1):157-64. PubMed ID: 25712293
[TBL] [Abstract][Full Text] [Related]
2. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
[TBL] [Abstract][Full Text] [Related]
3. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
4. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.
Tsapralis D; Panayiotides I; Peros G; Liakakos T; Karamitopoulou E
World J Gastroenterol; 2012 Jan; 18(2):150-5. PubMed ID: 22253521
[TBL] [Abstract][Full Text] [Related]
5. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
6. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.
Hanna WM; Kwok K
Mod Pathol; 2006 Apr; 19(4):481-7. PubMed ID: 16444193
[TBL] [Abstract][Full Text] [Related]
7. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance.
Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J
Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098
[TBL] [Abstract][Full Text] [Related]
9. Detection of Gene Amplification by Multiplex Ligation-Dependent Probe Amplification in Comparison with In Situ Hybridization and Immunohistochemistry.
Tabarestani S; Ghaderian SM; Rezvani H
Asian Pac J Cancer Prev; 2015; 16(17):7997-8002. PubMed ID: 26625832
[TBL] [Abstract][Full Text] [Related]
10. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
11. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Wixom CR; Albers EA; Weidner N
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.
Dandachi N; Dietze O; Hauser-Kronberger C
Lab Invest; 2002 Aug; 82(8):1007-14. PubMed ID: 12177239
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of HER2 gene amplification and its protein expression in 165 cases of breast carcinoma: comparison of chromogenic in-situ hybridization and immunohistochemistry].
Shen DH; Wang FH; Yu YZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):457-60. PubMed ID: 17845758
[TBL] [Abstract][Full Text] [Related]
14. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
[TBL] [Abstract][Full Text] [Related]
15. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
[TBL] [Abstract][Full Text] [Related]
16. A study of HER2 gene amplification and protein expression in gastric cancer.
Yan B; Yau EX; Bte Omar SS; Ong CW; Pang B; Yeoh KG; Salto-Tellez M
J Clin Pathol; 2010 Sep; 63(9):839-42. PubMed ID: 20696687
[TBL] [Abstract][Full Text] [Related]
17. HER2 expression and its clinicopathological features in resectable gastric cancer.
Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
Dandachi N; Dietze O; Hauser-Kronberger C
Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594
[TBL] [Abstract][Full Text] [Related]
20. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
Mentrikoski MJ; Stoler MH
Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
